Unveiling a new regulator of programmed cell death
Researchers identify a protein with potential implications for treatments for apoptosis-resistant cancers
Nara Institute of Science and Technology
image: Zbtb38 promotes cell survival by activating X-linked inhibitor of apoptosis protein (XIAP) transcription, leading to the suppression of caspase-3-dependent apoptosis. Reduced Zbtb38 decreases XIAP expression and enhances apoptosis.
Credit: Assistant Professor Eishou Matsuda from the Nara Institute of Science and Technology, Japan
Ikoma, Japan — Our bodies are constantly deciding which cells should live and which should die, through a process called apoptosis. This type of programmed cell death enables organisms to remove damaged or potentially dangerous cells in a controlled way. Apoptosis is a balancing act—too little of it can allow abnormal cells to survive and grow into cancer, while too much can lead to developmental problems or degenerative diseases. This process is regulated by complex networks of chemical signals, including proteins that either promote or block apoptosis.
Among these proteins, X-linked inhibitor of apoptosis protein (XIAP) acts as a brake on apoptosis by directly inhibiting caspase-3, a key enzyme that executes the apoptosis process. However, despite its central role, scientists still struggle to understand how XIAP itself is controlled. This knowledge gap is particularly relevant in cancer; malignant cells often evade treatment by disabling proteins that normally trigger apoptosis, such as the well-studied p53 protein. Could XIAP’s regulatory pathways be independent of those of p53?
In a recent study, a research team led by Assistant Professor Eishou Matsuda and Dr. Toshiaki Shigeoka from the Nara Institute of Science and Technology (NAIST), Japan, tackled this question. They identified a transcription factor—a protein that switches genes on or off—that acts as a direct regulator of XIAP. Their paper, published in the Journal of Molecular Cell Biology on 03 July 2026, was co-authored by Hiroyuki Nagaoka, Shogo Tada, Dr. Yasumasa Bessho, and Dr. Yasumasa Ishida, also from NAIST, as well as Dr. Nunuk Aries Nurulita from the University of Muhammadiyah Purwokerto, Indonesia.
The team showed that reducing or silencing this transcription factor, called Zbtb38, consistently lowered XIAP levels and triggered apoptosis across multiple cell types including cancer cells, regardless of p53 status. Restoring XIAP in Zbtb38-depleted cells reversed the increase in apoptosis and restored cell survival, confirming it as a direct downstream target. Through detailed molecular analyses, the researchers found that Zbtb38 binds specific DNA sequences called E-box motifs that are upstream of the XIAP gene and activates its transcription.
Further experiments showed the importance of Zbtb38 during development. Loss of Zbtb38 in embryonic stem cells and mouse embryos reduced XIAP and increased apoptosis during differentiation. Interestingly, an analysis of large-scale human tumor datasets revealed that both Zbtb38 and XIAP are strongly expressed in many tumor types, with higher Zbtb38 levels linked to more aggressive disease.
Taken together, the results point to a possible new strategy for controlling apoptosis in various disease contexts. “Our study provides new insights into a potentially universal mechanism of apoptosis regulation via the Zbtb38–XIAP axis. In the future, these findings may contribute to biomedical fields such as cancer therapy and regenerative medicine, where precise control of cell survival and cell death is essential,” remarks Dr. Matsuda.
Continued research on these important regulatory mechanisms will hopefully unlock their full therapeutic potential, as Dr. Matsuda concludes: “Future studies exploring Zbtb38's broader transcriptional network and context-specific interactions will be key to further elucidate its physiological and pathological functions.”
###
Resource
Title: Zbtb38 transcriptionally activates XIAP to regulate apoptosis in development and cancer
Authors: Toshiaki Shigeoka, Hiroyuki Nagaoka, Nunuk Aries Nurulita, Shogo Tada, Yasumasa Bessho, Yasumasa Ishida, and Eishou Matsuda
Journal: Journal of Molecular Cell Biology
DOI: 10.1093/jmcb/mjag011
Information about the Functional Genomics and Medicine laboratory can be found at the following website: https://bsw3.naist.jp/ishida/?cate=431
About Nara Institute of Science and Technology (NAIST)
Established in 1991, Nara Institute of Science and Technology (NAIST) is a national university located in Kansai Science City, Japan. In 2018, NAIST underwent an organizational transformation to promote and continue interdisciplinary research in the fields of biological sciences, materials science, and information science. Known as one of the most prestigious research institutions in Japan, NAIST lays a strong emphasis on integrated research and collaborative co-creation with diverse stakeholders. NAIST envisions conducting cutting-edge research in frontier areas and training students to become tomorrow's leaders in science and technology.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.